Marker Therapeutics reports encouraging data for MT-601 in relapsed B cell lymphomas.

Marker Therapeutics presented Phase 1 APOLLO study data on MT-601, an immunotherapy for relapsed B cell lymphomas, at the ASH Annual Meeting. The study showed encouraging preliminary efficacy and a robust safety profile with no dose-limiting toxicities or immune-effector cell-associated neurotoxicity syndrome. Data from the dose escalation cohort demonstrated no immune-effector cell-associated neurotoxicity syndrome.